Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Get Free Report) saw a significant drop in short interest in December. As of December 31st, there was short interest totalling 16,400 shares, a drop of 34.4% from the December 15th total of 25,000 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is presently ∞ days.
Basilea Pharmaceutica Stock Performance
Basilea Pharmaceutica stock remained flat at $52.83 during mid-day trading on Wednesday. The company has a fifty day moving average price of $52.83 and a 200 day moving average price of $51.07. Basilea Pharmaceutica has a 1-year low of $38.60 and a 1-year high of $52.83.
Analysts Set New Price Targets
Separately, HC Wainwright raised Basilea Pharmaceutica to a "strong-buy" rating in a research report on Monday, September 23rd.
Check Out Our Latest Stock Analysis on Basilea Pharmaceutica
About Basilea Pharmaceutica
(
Get Free Report)
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
Featured Articles
Before you consider Basilea Pharmaceutica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Basilea Pharmaceutica wasn't on the list.
While Basilea Pharmaceutica currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
